# Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

> **NCT05001880** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 66 (estimated)

## Conditions studied

- Peritoneal Malignant Mesothelioma

## Interventions

- **BIOLOGICAL:** Atezolizumab
- **BIOLOGICAL:** Bevacizumab
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Carboplatin
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Cytoreductive Surgery
- **DRUG:** Hyperthermic Intraperitoneal Chemotherapy
- **DRUG:** Pemetrexed
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT05001880
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-22
- **Primary completion:** 2026-08-20
- **Final completion:** 2026-08-20
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05001880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05001880, "Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT05001880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*